First, after a series of ex vivo pooled knockin screenings and sequencing of engineered T cells with TCR stimulation in the presence or absence of TGF-β1, a subset of T cells incorporated with a novel chimeric TGF-βR2-41BB construct showed distinct phenotypes and functions characterized by powerful tumor killing capacity in vitro (Fig. 1). This evidence concerns the gene TGFBR2 and neoplasm.